Elicera Therapeutics AB (publ) (8E8.F)

0.0480 -0.0092 (-16.08%) As of 08:12AM CEST. Market open.

Elicera Therapeutics AB (publ)

World Trade Centre Gothenburg
Floor 7 Mässans gata 10
Gothenburg 412 51
Sweden
46 7 03 31 90 51
https://www.elicera.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 2

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jamal El-Mosleh M.Sc.	CEO & Co-Founder	N/A	N/A	1981
Prof. Magnus Essand	Chief Science Officer, Co-Founder & Director	N/A	N/A	1964
Mr. Di Yu	Co-Founder & Head of Transitional Research	N/A	N/A	1985
Mr. Ingvar Karlsson	Chief Financial Officer	N/A	N/A	1956
Ms. Anna Koptina Gultekin	Head of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/II clinical trial for neuroendocrine tumors indications; ELC-201 for the treatment of various injectable solid tumors; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy for the treatment of solid tumors. Elicera Therapeutics AB (publ) has collaboration with the Josep Carreras Leukemia Research Institute to provide iTANK platform. The company was incorporated in 2014 and is based in Gothenburg, Sweden.

Corporate Governance

Elicera Therapeutics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.